selected publications
-
Antibody-Drug Conjugates in Urothelial Carcinomas.
Current oncology reports.
2020
Information Resource
GET IT
Times cited: 7 -
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 447 -
Treatment Outcomes of Immune-Related Cutaneous Adverse Events.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 184 -
MCL1 and DEDD Promote Urothelial Carcinoma Progression.
Molecular cancer research : MCR.
2019
Academic Article
GET IT
Times cited: 5 -
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Cancer.
2018
Academic Article
GET IT
Times cited: 36 -
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 170 -
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 113 -
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 110 -
Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes.
Cell reports.
2018
Academic Article
GET IT
Times cited: 64 -
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 400 -
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 87 -
Oncologist use and perception of large panel next-generation tumor sequencing.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017
Academic Article
GET IT
Times cited: 32 -
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
PLoS medicine.
2017
Academic Article
GET IT
Times cited: 249 -
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
European urology focus.
2017
Academic Article
GET IT
Times cited: 6 -
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet (London, England).
2016
Academic Article
GET IT
Times cited: 1718 -
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
The Lancet. Oncology.
2016
Academic Article
GET IT
Times cited: 580 -
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
European urology.
2016
Academic Article
GET IT
Times cited: 59 -
Genomic characterization of response to chemoradiation in urothelial bladder cancer.
Cancer.
2016
Academic Article
GET IT
Times cited: 52 -
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Lancet (London, England).
2016
Academic Article
GET IT
Times cited: 3029 -
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.
Nature genetics.
2016
Academic Article
GET IT
Times cited: 142 -
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
Cancer.
2015
Academic Article
GET IT
Times cited: 25 -
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.
The Journal of urology.
2015
Academic Article
GET IT
Times cited: 50 -
Genomic Characterization of Upper Tract Urothelial Carcinoma.
European urology.
2015
Academic Article
GET IT
Times cited: 198 -
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.
Clinical genitourinary cancer.
2015
Academic Article
GET IT
Times cited: 3 -
DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.
BMC cancer.
2015
Academic Article
GET IT
Times cited: 21 -
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
The oncologist.
2015
Academic Article
GET IT
Times cited: 37 -
Novel molecular targets for urothelial carcinoma.
Expert opinion on therapeutic targets.
2015
Information Resource
GET IT
Times cited: 9 -
First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.
Hematology/oncology clinics of North America.
2014
Information Resource
GET IT
Times cited: 18 -
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
European journal of cancer.
2014
Academic Article
GET IT
Times cited: 78 -
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
Clinical genitourinary cancer.
2014
Academic Article
GET IT
Times cited: 2 -
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Cancer discovery.
2014
Academic Article
GET IT
Times cited: 502 -
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
European urology.
2014
Academic Article
GET IT
Times cited: 116 -
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.
Cancer discovery.
2014
Academic Article
GET IT
Times cited: 102 -
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
Cancer medicine.
2014
Academic Article
GET IT
Times cited: 77 -
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2014
Academic Article
GET IT
Times cited: 59 -
Comprehensive molecular characterization of urothelial bladder carcinoma.
Nature.
2014
Academic Article
GET IT
Times cited: 2391 -
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
Investigational new drugs.
2013
Academic Article
GET IT
Times cited: 305 -
Molecular targets on the horizon for kidney and urothelial cancer.
Nature reviews. Clinical oncology.
2013
Information Resource
GET IT
Times cited: 21 -
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
Journal of the National Cancer Institute.
2013
Academic Article
GET IT
Times cited: 79 -
Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.
Frontiers in pharmacology.
2013
Article
GET IT
Times cited: 21 -
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
European urology.
2012
Academic Article
GET IT
Times cited: 107 -
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research.
Urologic oncology.
2012
Information Resource
GET IT
Times cited: 5 -
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2012
Academic Article
GET IT
Times cited: 174 -
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.
The Lancet. Oncology.
2010
Information Resource
GET IT
Times cited: 115 -
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010
Article
GET IT
Times cited: 9